VCYT — Veracyte Share Price
Last trade - 00:00- $1.96bn
- $1.79bn
- $117.48m
- 53
- 37
- 57
- 49
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.77 | ||
| Price to Tang. Book | 10.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.49 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.83% | ||
| Return on Equity | -9.55% | ||
| Operating Margin | -41.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 65.08 | 71.95 | 92.01 | 120.37 | 117.48 | 213.7 | 267.77 | 18.87% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.
Directors
- Bonnie Anderson CHM (63)
- Marc Stapley CEO (51)
- Rebecca Chambers CFO (43)
- Tina Nova CEX (67)
- Robert Brainin EVP (50)
- Bill Zondler SVP
- Beverly Alley CAO (58)
- Giulia Kennedy CSO (61)
- John Bishop LED (76)
- Muna Bhanji IND (58)
- Frederick Cohen IND (64)
- Karin Eastham IND (71)
- Robert Epstein IND (66)
- Kevin Gordon IND (58)
- Jens Holstein IND (57)
- Evan Jones IND (64)
- Last Annual
- December 31st, 2020
- Last Interim
- September 30th, 2021
- Incorporated
- August 15th, 2006
- Public Since
- October 30th, 2013
- No. of Employees
- 320
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 71,043,062
- Address
- 6000 Shoreline Ct Ste 300, SOUTH SAN FRANCISCO, 94080-7606
- Web
- https://www.veracyte.com/
- Phone
- +1 6502436300
- Contact
- Tracy Morris
- Auditors
- Ernst & Young LLP
Latest News for VCYT
Upcoming Events for VCYT
Q4 2021 Veracyte Inc Earnings Release
Q1 2022 Veracyte Inc Earnings Release
Veracyte Inc Annual Shareholders Meeting
Similar to VCYT
4d Pharma
NASDAQ Global Market
89bio
NASDAQ Global Market
Acceleron Pharma
NASDAQ Global Market
AcelRx Pharmaceuticals
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
FAQ
As of Today at 13:02 UTC, shares in Veracyte are trading at $27.56. This share price information is delayed by 15 minutes.
Shares in Veracyte last closed at $27.56 and the price had moved by -50.23% over the past 365 days. In terms of relative price strength the Veracyte share price has underperformed the S&P500 Index by -56.56% over the past year.
The overall consensus recommendation for Veracyte is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Veracyte does not currently pay a dividend.
Veracyte does not currently pay a dividend.
Veracyte does not currently pay a dividend.
To buy shares in Veracyte you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $27.56, shares in Veracyte had a market capitalisation of $1.96bn.
Here are the trading details for Veracyte:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: VCYT
Based on an overall assessment of its quality, value and momentum Veracyte is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Veracyte is $61.38. That is 122.71% above the last closing price of $27.56.
Analysts covering Veracyte currently have a consensus Earnings Per Share (EPS) forecast of -$1.14 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Veracyte. Over the past six months, its share price has underperformed the S&P500 Index by -29.98%.
As of the last closing price of $27.56, shares in Veracyte were trading -34.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Veracyte PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $27.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Veracyte's management team is headed by:
- Bonnie Anderson - CHM
- Marc Stapley - CEO
- Rebecca Chambers - CFO
- Tina Nova - CEX
- Robert Brainin - EVP
- Bill Zondler - SVP
- Beverly Alley - CAO
- Giulia Kennedy - CSO
- John Bishop - LED
- Muna Bhanji - IND
- Frederick Cohen - IND
- Karin Eastham - IND
- Robert Epstein - IND
- Kevin Gordon - IND
- Jens Holstein - IND
- Evan Jones - IND